Navigation Links
Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
Date:1/17/2008

LA JOLLA, Calif., Jan. 17 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced today that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of Diabetic Ulcers.

The Board of Immunosyn was advised as to the success of this important phase of the "Proof of Concept Trial" by Argyll Biotechnologies, LLC its strategic partner and largest shareholder. Argyll Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement.

The primary purpose of the "Proof of Concept Trial" is to further evaluate the safety and efficacy of SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic Polyneuropathy in Type 1 Diabetes Mellitus by both subcutaneous injection and by topical application.

Regarding the "Proof of Concept Trial," Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPath, FMedSci, Chief Scientist and Consultant Medical Officer for Argyll Biotechnologies, LLC stated that, "This first very important phase in the development of SF-1019, which was undertaken at a European venue, has indicated that SF-1019 promotes wound healing and almost certainly induces growth factors." "When systemically delivered, SF-1019 has shown the rapid resolution of long standing chronic lesions which is very impressive. And the topical application of SF-1019, while showing promise, in that a 5mm deep wound became closed, needs, as expected, unlike the subcutaneous method, more short-term development in order to improve the delivery methodology," he added.

Clinical Director for Argyll Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP, has also advised that, "Because of the positive results, which both the independent clinical team and I have observed during the first phase of the "Proof of Concept
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Immunosyn Corporation Names Stephen Ferrone as CEO
2. Immunosyn Corporation to Begin Trading
3. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Javlin continues to fulfill its worldwide ... a larger team, with the intention to better serve ... in the U.S. and Canada. , Javlin Inc., the ... growth in 2014 with its strongest earnings to date, ... platform, CloverETL. To accelerate further progress and ensure exceptional ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The annual aesthetic ... Surgery (ASAPS), was held in Montreal from May 14-19th. ... for aesthetic professionals from around the world; dedicating itself exclusively ... the many renowned plastic surgeons to attend this ... the six-day event, Dr. Vitenas was given the honor of ...
(Date:5/29/2015)... Healthpointe is excited to announce that they are now ... in Orange County. The Supartz Therapy is a cost-effective, ... for patients with osteoarthritis, and will be administered by ... of Healthpointe. Supartz is an injection of made from ... a natural substance found in joint cartilage. Also known ...
(Date:5/29/2015)... Metamora, Michigan (PRWEB) May 29, 2015 ... region and can cause significant physical, sexual, and psychological ... life altering disorder of Vulvodynia. The actual diagnosis is ... Excellence in Endometriosis, they realize that this problem can ... is experiencing any of these symptoms, they need to ...
(Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
Breaking Medicine News(10 mins):Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... The New Women's Health Initiative (WHI) suggests, a prolonged ... carbohydrates results in negligible weight gain. // ... postmenopausal women Vis a Vis variations in consumed foods ... advised to reduce the fat consumption to 20% of ...
... body cavity rather than the conventional intravenous route, seems to ... cancer patients, according to a latest study. // ... among American women. In line with the above finding, the ... all ovarian cancer patients. ,This new treatment modality ...
... help in slowing down the progress of Alzheimer's disease, ... and Chile. The healthy brain // ... their study, to be published in the American Chemical ... surgery, has the potential to destroy beta-amyloid fibrils and ...
... Rotateq and Rotarix in more than 1, 30, 000 ... The vaccines have been found to be 98% and ... 1/3rd of all hospital infections worldwide. ,A ... 1990’s. This however, was withdrawn from the market owing ...
... A leaflet claiming that traditional Chinese medicine was safer ... code in the UK, an industry watchdog said on ... essential treatment from qualified doctors for serious medical conditions, ... produced by Ever Well Ltd, also claimed that serious ...
Cached Medicine News:Health News:Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy 2Health News:Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection 2Health News:Chinese medicine leaflet broke advertising code 2
(Date:5/28/2015)... Research and Markets ( ... "United States Medical Adhesives Market Forecast and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , , The ... United States is projected to register ... device manufacturers across the US are expanding their ...
(Date:5/28/2015)... May 28, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... Therapeutics WebcastWhen: , Thursday, June 4 at 1:00 p.m. ... , Live on the Internet.  Simply log onto our ... during the live event, a replay of the webcast ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. Isis ...
(Date:5/28/2015)... Md. , May 28, 2015 ... it will be a supporting organization of the ... and sterilization in 2016. Johnson & ... series of high-profile superbug infections in endoscopes. J&J ... health issues between 1976 and 2003 on advances ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2
... Science, public health, and regulatory highlights for ... nformation in this document is designed for credentialed journalists. ... April 18, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... any regulatory or enforcement actions due to legal limitations. ...
... (Nasdaq: LMNX ) today announced that it expects ... Monday, May 9, 2011. A press release announcing the results ... (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the first quarter ended March 31, 2011, ...
Cached Medicine Technology:FDA News & Notes - Week of April 18, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: